drugset
drugset / Trial / NCT03556228

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

NCT03556228 ↗

Phase 1/2 Recruiting 242 enrolled VM Oncology, LLC
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

Timeline

Start
2018-06-08
Primary completion
2027-12
Completion
2028-06

Drugs

EvaluationDrugModalityDoseRoute
Subject VMD-928 Unknown 100 mg Oral
Subject VMD-928 Unknown 300 mg Oral
Background Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

adenoid cystic carcinoma esophageal cancer head and neck squamous cell carcinoma hypopharynx cancer larynx cancer lip cancer malignant pancreatic neoplasm mesothelioma nasopharyngeal carcinoma non-small cell lung carcinoma salivary gland carcinoma small cell lung carcinoma tonsil cancer tracheal cancer